A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response.
In a significant proportion of melanoma patients, CTL specific for the melan-A(26/7-35) epitope can be detected in peripheral blood using HLA-A2/peptide tetramers. However, the functional capacity of these CTL has been controversial, since although they prove to be effective killers after in vitro e...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2000
|
| _version_ | 1826305752187273216 |
|---|---|
| author | Dunbar, P Smith, C Chao, D Salio, M Shepherd, D Mirza, F Lipp, M Lanzavecchia, A Sallusto, F Evans, A Russell-Jones, R Harris, A Cerundolo, V |
| author_facet | Dunbar, P Smith, C Chao, D Salio, M Shepherd, D Mirza, F Lipp, M Lanzavecchia, A Sallusto, F Evans, A Russell-Jones, R Harris, A Cerundolo, V |
| author_sort | Dunbar, P |
| collection | OXFORD |
| description | In a significant proportion of melanoma patients, CTL specific for the melan-A(26/7-35) epitope can be detected in peripheral blood using HLA-A2/peptide tetramers. However, the functional capacity of these CTL has been controversial, since although they prove to be effective killers after in vitro expansion, in some patients they have blunted activation responses ex vivo. We used phenotypic markers to characterize melan-A tetramer(+) cells in both normal individuals and melanoma patients, and correlated these markers with ex vivo assays of CTL function. Melanoma patients with detectable melan-A tetramer(+) cells in peripheral blood fell into two groups. Seven of thirteen patients had a CCR7(+) CD45R0(-) CD45RA(+) phenotype, the same as that found in some healthy controls, and this phenotype was associated with a lack of response to melan-A peptide ex vivo. In the remaining six patients, melan-A tetramer(+) cells were shifted toward a CCR7(-) CD45R0(+) CD45RA(-) phenotype, and responses to melan-A peptide could be readily demonstrated ex vivo. When lymph nodes infiltrated by melan-A-expressing melanoma cells were examined, a similar dichotomy emerged. These findings demonstrate that activation of melan-A-specific CTL occurs in only some patients with malignant melanoma, and that only patients with such active immune responses are capable of responding to Ag in ex vivo assays. |
| first_indexed | 2024-03-07T06:37:36Z |
| format | Journal article |
| id | oxford-uuid:f8309693-1d90-490a-8f0d-ab462c4460a2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:37:36Z |
| publishDate | 2000 |
| record_format | dspace |
| spelling | oxford-uuid:f8309693-1d90-490a-8f0d-ab462c4460a22022-03-27T12:48:29ZA shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f8309693-1d90-490a-8f0d-ab462c4460a2EnglishSymplectic Elements at Oxford2000Dunbar, PSmith, CChao, DSalio, MShepherd, DMirza, FLipp, MLanzavecchia, ASallusto, FEvans, ARussell-Jones, RHarris, ACerundolo, VIn a significant proportion of melanoma patients, CTL specific for the melan-A(26/7-35) epitope can be detected in peripheral blood using HLA-A2/peptide tetramers. However, the functional capacity of these CTL has been controversial, since although they prove to be effective killers after in vitro expansion, in some patients they have blunted activation responses ex vivo. We used phenotypic markers to characterize melan-A tetramer(+) cells in both normal individuals and melanoma patients, and correlated these markers with ex vivo assays of CTL function. Melanoma patients with detectable melan-A tetramer(+) cells in peripheral blood fell into two groups. Seven of thirteen patients had a CCR7(+) CD45R0(-) CD45RA(+) phenotype, the same as that found in some healthy controls, and this phenotype was associated with a lack of response to melan-A peptide ex vivo. In the remaining six patients, melan-A tetramer(+) cells were shifted toward a CCR7(-) CD45R0(+) CD45RA(-) phenotype, and responses to melan-A peptide could be readily demonstrated ex vivo. When lymph nodes infiltrated by melan-A-expressing melanoma cells were examined, a similar dichotomy emerged. These findings demonstrate that activation of melan-A-specific CTL occurs in only some patients with malignant melanoma, and that only patients with such active immune responses are capable of responding to Ag in ex vivo assays. |
| spellingShingle | Dunbar, P Smith, C Chao, D Salio, M Shepherd, D Mirza, F Lipp, M Lanzavecchia, A Sallusto, F Evans, A Russell-Jones, R Harris, A Cerundolo, V A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. |
| title | A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. |
| title_full | A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. |
| title_fullStr | A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. |
| title_full_unstemmed | A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. |
| title_short | A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. |
| title_sort | shift in the phenotype of melan a specific ctl identifies melanoma patients with an active tumor specific immune response |
| work_keys_str_mv | AT dunbarp ashiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT smithc ashiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT chaod ashiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT saliom ashiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT shepherdd ashiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT mirzaf ashiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT lippm ashiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT lanzavecchiaa ashiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT sallustof ashiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT evansa ashiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT russelljonesr ashiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT harrisa ashiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT cerundolov ashiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT dunbarp shiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT smithc shiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT chaod shiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT saliom shiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT shepherdd shiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT mirzaf shiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT lippm shiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT lanzavecchiaa shiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT sallustof shiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT evansa shiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT russelljonesr shiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT harrisa shiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse AT cerundolov shiftinthephenotypeofmelanaspecificctlidentifiesmelanomapatientswithanactivetumorspecificimmuneresponse |